Need Help?

Resistance to MAPK-inhibitor induces internal duplication in BRAF_Oscar Krijsman

2 BRAFV600E cell lines that have been made resistance to 1. the BRAF inhibitor PLX4720 and 2. the combination therapy of dabrafenib and trametinib seem to have a internal duplication in the kinase domain. We would like to know if this is caused by a translocation.

Request Access

Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.

Study ID Study Title Study Type
EGAS00001001304 Other

This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.

ID File Type Size Located in
EGAF00000923755 cram 39.1 GB
EGAF00000923756 cram 39.8 GB
EGAF00000929261 cram 37.6 GB
EGAF00000929262 cram 37.9 GB
4 Files (154.4 GB)